Paul Carlos Becker, Mandy Michelle Güth-Steffens, Katina Lazarow, Niklas Sonntag, Doreen Braun, Salam Ali Masfaka, Kostja Renko, Lutz Schomburg, Josef Köhrle, Jens Peter von Kries, Ulrich Schweizer, Gerd Krause, Jonas Protze
BACKGROUND: TRIAC (3,5,3'-triiodothyroacetic acid) is a T3-receptor agonist pharmacologically used in patients to mitigate T3 resistance. It is additionally explored to treat some symptoms of patients with inactivating mutations in the thyroid hormone (TH) transporter MCT8 (SLC16A2). MCT8 is expressed along the blood-brain-barrier, on neurons, astrocytes, and oligodendrocytes. Hence, pathogenic variants in MCT8 limit the access of TH into and their functions within the brain. TRIAC was shown to enter the brain independently of MCT8 and to modulate expression of TH-dependent genes...
May 27, 2024: Thyroid: Official Journal of the American Thyroid Association